Compare Moderna, Inc. (MRNA) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Nasdaq Inc — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Nasdaq Inc trades at $93.65 (market cap $51.63B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Nasdaq Inc pays a 1.26% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Nasdaq Inc for 126 Days on average.
| MRNA | NDAQ | |
|---|---|---|
Market Cap | $78.65B | $51.63B |
Volume | 37,373,437 | 2,668,175 |
Sector | Health | Financials |
52-Week High | $203.46 | $100.98 |
52-Week Low | $22.36 | $76.85 |
Typical Hold Time | 59 Days | 126 Days |
Enterprise Value | $74.80B | $58.09B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Nasdaq (NDAQ) trades at $92.37, up 0.48% with a bullish technical signal. The company shows strong fundamentals with Q2 2026 EPS beating expectations at $1.07 versus $0.984, and revenue growth from $7.4B in 2024 to $8.3B in 2025. Recent news highlights Nasdaq's AI-powered Calypso platform adoption by HSBC and Moderna joining the Nasdaq-100 Index, signaling business momentum. Valuation metrics include P/E of 26.93 and P/S of 6.07, with analyst consensus price target at $110.43.
NDAQ presents a favorable outlook with consistent earnings beats and strategic AI integration driving growth. Risks include market volatility sensitivity and debt levels, but strong institutional support and bullish analyst ratings suggest upside potential. The stock's current price offers a 19.6% discount to consensus target, making it attractive for growth-oriented investors seeking exposure to financial technology and market infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
